ERCC1和XRCC3基因多态性在接受含铂方案化疗NSCLC中的疗效预测作用  

Predictive Role of ERCC1 and XRCC3 Gene Polymorphism on Response of Platinum-based Chemotherapy in Advanced NSCLC

作　　者：任胜祥[1] 周彩存[1] 周崧雯[1] 张玲[1] 苏春霞[1] 张增利[1] 邓沁芳[1] 张颉[1] 

机构地区：[1]上海市肺科医院,同济大学肿瘤研究所,上海200433

出　　处：《肿瘤学杂志》2009年第8期706-710,共5页Journal of Chinese Oncology

基　　金：上海市科委重大项目基金(06DZ19502)

摘　　要：[目的]探讨DNA修复基因ERCC1118和XRCC3241多态性对于接受一线含铂化疗方案的非小细胞肺癌(NSCLC)患者的疗效预测作用。[方法]130例晚期接受含铂化疗的NSCLC患者进入研究,应用Taqman探针结合实时荧光PCR方法分析其外周血基因多态性,分析ERCC1118和XRCC3241多态性与疗效、疾病进展时间和总体生存期之间的关系。[结果]130例患者的总体有效率为20%,中位生存时间为15个月。ERCC1118和XRCC3241多态性与疗效无显著相关性。ERCC1118基因型C/T或T/T患者的生存时间显著延长(P=0.003)。Cox多因素分析显示,ERCC1118基因型C/T或T/T以及化疗有效患者的生存期显著延长。[结论]DNA修复基因ERCC1118基因型C/T或T/T多态性可以延长NSCLC患者铂类治疗后的生存时间。[Purpose] To investigate the predictive role of ERCC1 118 and XRCC3 241 polymorphism on response in advanced NSCLC patients receiving first-line platinum-based chemotherapy. [ Methods] One hundred and thirty cases with advanced NSCLC treated with platinum-based enrolled in this study, using Taqman probe combined with real time fluorescent PCR detecting gene polymorphism in peripheral blood, analysis of the relationship of ERCC1 118 and XRCC3 241 polymorphism with efficacy, time to progression and overall survival. [Results] The overall response rate was 20%, median survival time was 15 months. There was no significant correlation of ERCC1 118 and XRCC3 241 polymorphism with efficacy. Median survival time in patients with ERCC1 118 genotype C/T or T/T was significant prolonged （P=0.003）.Cox multivariate analysis showed the survival time was significant prolonged in patients with ERCC1 118 genotype C/T or T/T and chemotherapy in effect. [Conclusion] DNA repair gene ERCC1 118 genotype C/T or T/T polymorphism can significantly prolong the overall survival time in patients with NSCLC receiving platinum-based chemotherapy. DNA

关 键 词：DNA修复基因 ERCC1 XRCC3 基因多态性 癌 非小细胞肺 

分 类 号：R734.2[医药卫生—肿瘤]